CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Carver Biosciences
Company Type: Therapeutic development
Main focus: Developing CRISPR-based therapies for RNA viruses that infect humans
Company stage: Pre-clinical
Diseases: Human RNA viral infections
Genome-editing tool: CRISPR-Cas13
Funding stage: Seed
Location: Boston, Massachusetts, USA
Website: Carver Biosciences - Home
Pipeline:
Partners:
Carver Biosciences is a biotechnology company focused on developing broad-spectrum anti-virals using CRISPR technology. Carver’s approach is a programmable, platform technology that could provide treatment options for various human-infecting RNA viruses. The company’s technology is based on the programmable function of CRISPR’s guide RNA sequence. Currently, Carver is investigating the use of CRISPR-Cas13 to target and destroy respiratory viruses at the RNA level.
